UDC

[616.71-008.1+616.71-009.7]:611.018.4

DOI

10.37482/2687-1491-Z246

Authors

Elena A. Galashina* ORCID: https://orcid.org/0000-0001-6209-9120
*V.I. Razumovsky Saratov State Medical University
(Saratov, Russia)

Abstract

According to the World Health Organization, osteoporosis is one of most common pathologies of the musculoskeletal system. Abnormal bone remodelling is known to lead to the progression of osteoporosis and osteopenia and a significant increase in the risk of bone fractures. To study the processes of bone tissue resorption and formation, various indicators are used that reflect the activity of the cellular elements of bone tissue and the state of its matrix. The purpose of this review was to analyse current concepts about the pathogenetic role of bone metabolism markers and regulators in the development of osteoporosis and osteopenia for the earliest possible diagnosis of these pathologies. We reviewed 570 literature sources retrieved from the digital databases PubMed, PubMed Central, eLIBRARY.RU as well as the search platforms Google Scholar, SpringerLink and Elsevier published between 2009 and 2023. The search was performed in Russian and English using the following keywords and their combinations: bone tissue, remodelling, resorption, bone formation, osteoporosis, osteopenia, cytokines, RANKL/RANK/OPG system. The exclusion criteria narrowed the list to 47 most significant studies providing comprehensive insights into certain aspects of osteoporosis and osteopenia. The literature analysis showed that some markers of bone tissue remodelling, as well as inflammatory mediators, have pathogenetic significance in the development of osteoporosis and osteopenia and can be used for early diagnosis of these diseases. Searching for new molecular markers of abnormal bone remodelling appears to be a promising area of research on osteoporosis and osteopenia.

Keywords

bone tissue, remodelling, resorption, bone formation, osteoporosis, osteopenia, cytokines, RANKL/ RANK/OPG system

References

1. Galchenko A.V. Influence of Lifestyle Factors on Bone Metabolism and the Risk of Osteoporosis. Russ. J. Prev. Med., 2022, vol. 25, no. 6, pp. 96–107 (in Russ.). https://doi.org/10.17116/profmed20222506196
2. Ignat’ev A.M., Turchin N.I. Instrumental’nye i biokhimicheskie pokazateli sostoyaniya kostnoy tkani pri osteomalyatsii i osteoporoze [Instrumental and Biochemical Indicators of the Bone Tissue State in Osteomalacia and Osteoporosis]. Travma, 2020, vol. 21, no. 6, pp. 16–20. https://doi.org/10.22141/1608-1706.6.21.2020.223883
3. Bayramov A.A., Maevskiy E.I., Zelener A.O., Karonova T.L., Shabanov P.D. Protsessy kostnogo remodelirovaniya na etapakh korrektsii eksperimental’nogo indutsirovannogo osteoporoza [Bone Remodeling Processes at the Stages of Correction of Experimentally Induced Osteoporosis]. Vestnik Novgorodskogo gosudarstvennogo universiteta, 2020, no. 1, pp. 23–29. https://doi.org/10.34680/2076-8052.2020.1 (117).23-29
4. Vasilyeva L.V., Bezzubtseva E.N., Gosteva E.V., Evstratova E.F. The Role of Genetic and Metabolic Disorders in Osteoporosis. Med. Her. South Russ., 2021, vol. 12, no. 1, pp. 6–13. https://doi.org/10.21886/2219-8075-2021-12-1-6-13
5. Dolgova L.N., Krasivina I.G. Osteoporoz i osteopeniya u patsientov s metabolicheskim sindromom [Osteoporosis and Osteopenia in Patients with Metabolic Syndrome]. RMZh. Meditsinskoe obozrenie, 2015, vol. 23, no. 17, pp. 1006– 1009.
6. Yalaev B.I., Khusainova R.I. Epigenetic Regulation of Bone Remodeling and Its Role in the Pathogenesis of Primary Osteoporosis. Vavilov J. Genet. Breed., 2023, vol. 27, no. 4, pp. 401–410. https://doi.org/10.18699/VJGB-23-48
7. Simrok V.V., Adunts A.G., Rumyantseva Z.S. Markery kostnogo obmena, vitamin D i paratgormon u zhenshchin v dinamike lecheniya postmenopauzal’nogo osteoporoza ibandronatom [Bone Metabolism Markers, Vitamin D, and Parathyroid Hormone in Women in the Dynamics of Postmenopausal Osteoporosis Treatment with Ibandronate]. Universitetskaya klinika, 2020, no. 3, pp. 12–17. https://doi.org/10.26435/uc.v0i3 (36).598
8. Verbovoy A.F., Pashentseva A.V., Sharonova L.A. Osteoporoz: sovremennoe sostoyanie problemy [Osteoporosis: Current State of the Art]. Terapevticheskiy arkhiv, 2017, vol. 89, no. 5, pp. 90–96. https://doi.org/10.17116/terarkh201789590-97
9. Dudinskaya E.N., Brailova N.V., Kuznetsova V.A., Tkacheva O.N. Osteoporosis in the Elderly. Osteoporos. Bone Dis., 2019, vol. 22, no. 3, pp. 34–40 (in Russ.). https://doi.org/10.14341/osteo12352
10. Kabalyk M.A. Biomarkery i uchastniki remodelirovaniya subkhondral’noy kosti pri osteoartroze [Biomarkers of Subchondral Bone Remodeling in Osteoarthritis]. Tikhookeanskiy meditsinskiy zhurnal, 2017, no. 1, pp. 36–41.
11. Masheyko I.V. Biokhimicheskie markery v otsenke protsessov remodelirovaniya kostnoy tkani pri osteopenii i osteoporoze [Biochemical Markers for the Evaluation of Bone Tissue Remodeling in Osteopenia and Osteoporosis]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, vol. 15, no. 2, pp. 149–153.
12. Kiseleva I.V. Izmenenie markerov metabolizma kostnoy tkani v syvorotke krovi u bol’nykh s osteoporozom [Changes in Bone Metabolism Markers in the Blood Serum of Patients with Osteoporosis]. Sovremennye problemy nauki i obrazovaniya, 2014, no. 3. Art. no. 552.
13. Singh S., Kumar D., Lal A.K. Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women. J. Clin. Diagn. Res., 2015, vol. 9, no. 8, pp. RC04–RC07. https://doi.org/10.7860/JCDR/2015/14857.6318
14. Kumalasari C., Siregar M.F.G., Edianto D., Tobing C.L., Adella C.A. Correlation of Osteocalcin Urine Levels with Bone Mass Density in Menopause Women in H. Adam Malik General Hospital Medan. Indian J. Public Health Res. Dev., 2020, vol. 11, no. 1, pp. 1011–1016. https://doi.org/10.37506/v11/i1/2020/ijphrd/193969
15. Markevich T.N. Shchelochnaya fosfataza kak marker metabolizma kosti [Alkaline Phosphatase as a Marker of Bone Metabolism]. Dostizheniya fundamental’noy, klinicheskoy meditsiny i farmatsii [Advancements in Fundamental and Clinical Medicine and Pharmacy]. Vitebsk, 2022, pp. 265–266.
16. Belova S.V., Gladkova E.V., Ulyanov V.Yu. Disorder of Subchondral Bone Remodeling and Activation of Lipid Peroxidation in the Early Osteoarthritis Pathogenesis. Prev. Clin. Med., 2023, no. 2, pp. 34–40 (in Russ.). https://doi.org/10.47843/2074-9120_2023_2_34
17. Saad M.A., Aboelwafa R.A., Elsayed E.H. Could Procollagen Type I N-Terminal Propeptide (PINP) and Bone Alkaline Phosphatase (B-ALP) Be Valid Alternative Diagnostic Markers to Dual X-Ray Absorptiometry (DEXA) in Elderly Females with Osteoporosis? An Egyptian Radiological and Laboratory Monocentric Study. Egypt. Rheumatol. Rehabil., 2021, vol. 48. Art. no. 20. https://doi.org/10.1186/s43166-021-00069-y
18. Zakharov I.S., Kolpinskiy G.I., Ushakova G.A., Vavin G.V. Biokhimicheskie markery v diagnostike narusheniy remodelirovaniya kostnoy tkani pri osteoporoze [Biochemical Markers in the Diagnosis of Bone Remodeling in Osteoporosis]. Vestnik Avitsenny, 2013, no. 4, pp. 119–123.
19. Jagtap V.R., Ganu J.V. Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis. Indian J. Clin. Biochem., 2012, vol. 27, no. 1, pp. 90–93. https://doi.org/10.1007/s12291-011-0185-4
20. Adugani S., Bannimath G., Sastry P. A Review on Biomarkers in Clinical Osteoporosis – Significance of Hydroxyproline. Biomed. Biotechnol. Res. J., 2021, vol. 5, no. 3, pp. 245–251. https://doi.org/10.4103/bbrj.bbrj_91_21
21. Vijaya V., Gurupadayyaa B.M., Chandana R.S., Manusmitha S.S., Raikar P.P., Purushotham S. Analysis of a Urinary Biomarker Hydroxyproline for Clinical Assessment in Osteoporosis Patients. Anal. Bioanal. Chem. Res., 2021, vol. 8, no. 4, pp. 481–491. https://doi.org/10.22036/ABCR.2021.266629.1581
22. Grebennikova T.A., Troshina V.V., Belaia Zh.E. Markers and Genetic Predictors of Osteoporosis in Routine Clinical Practice. Consilium medicum, 2019, vol. 21, no. 4, pp. 97–102. https://doi.org/10.26442/20751753.2019.4.190323
23. Demir M., Ulas T., Tutoglu A., Boyaci A., Karakas E.Y., Sezen H., Ustunel M., Bilinc H., Gencer M., Buyukhatipoglu H. Evaluation of Oxidative Stress Parameters and Urinary Deoxypyridinoline Levels in Geriatric Patients with Osteoporosis. J. Phys. Ther. Sci., 2014, vol. 26, no. 9, pp. 1405–1409. https://doi.org/10.1589/jpts.26.1405
24. Kuz’mina D.A., Vorontsov P.V. Biokhimicheskie metody otsenki kostnogo metabolizma. Markery i ikh klinicheskoe znachenie [Biochemical Methods of Assessment of Bone Metabolism. Markers and Their Clinical Value]. Meditsina: teoriya i praktika, 2018, vol. 3, no. S, pp. 99–106.
25. Bogdanov M.V. Biokhimicheskie i geneticheskie markery kostnogo remodelirovaniya pri osteoporoze u detey [Biochemical and Genetic Markers of Bone Remodelling in Osteoporosis in Children]. Sbornik nauchnykh tezisov i statey “Zdorov’e i obrazovanie v XXI veke”, 2009, vol. 11, no. 2, pp. 178–179.
26. Zakirov F.Kh., Krasil’nikov A.A., Lubyshev E.A., Chubanova G.R. Perspektivy ispol’zovaniya biomarkerov osteoporoza v diagnostike i lechenii [Perspectives of Usage of Osteoporosis Biomarkers in Diagnostics and Treatment]. Khirurgicheskaya praktika, 2019, no. 1, pp. 45–47. https://doi.org/10.17238/issn2223-2427.2019.1.45-47
27. Sukhareva A.S. Izuchenie kontsentratsii markera kostnoy destruktsii β-CrossLaps v syvorotke krovi zhenshchin v periode postmenopauzy, prozhivayushchikh v severnom regione [Study on the Concentration of the Bone Turnover Marker β-CrossLaps in the Blood Serum of Postmenopausal Women Living in the Northern Region]. Vysshaya shkola: nauchnye issledovaniya [Higher School: Scientific Research]. Moscow, 2019. Pt. 1, pp. 68–73.
28. Modagan P., Chand L., Menon G., Aruna L.P., Silambanan S. Association of N-Terminal Telopeptide-1 with BMD in Patients with Osteopenia and Osteoporosis. Res. Results Biomed., 2022, vol. 8, no. 1, pp. 82–90. https://doi.org/10.18413/2658-6533-2022-8-1-0-6
29. Bai R.-J., Li Y.-S., Zhang F.-J. Osteopontin, a Bridge Links Osteoarthritis and Osteoporosis. Front. Endocrinol. (Lausanne), 2022, vol. 13. Art. no. 1012508. https://doi.org/10.3389/fendo.2022.1012508
30. Al-Nejjar B.I., Abdul-Rasheed O.F., Al-Shamaa G.A. The Values of Osteopontin and Bone Specific Alkaline Phosphatase in Diagnosis of Osteoporosis. A Comparative Study. Med. J. Babylon, 2015, vol. 12, no. 4, pp. 986–998.
31. Vancea A., Serban O., Fodor D. Relationship Between Osteopontin and Bone Mineral Density. Acta Endocrinol. (Buchar.), 2021, vol. 17, no. 4, pp. 509–516. https://doi.org/10.4183/aeb.2021.509
32. Povoroznyuk V.V., Reznichenko N.A., Maylyan E.A. Rol’ immunnykh faktorov v patogeneze postmenopauzal’nogo osteoporoza [Role of Immune Factors in the Pathogenesis of Post Menopausal Osteoporosis]. Problemy osteologii, 2013, vol. 16, no. 3, pp. 3–7.
33. Nurullina G.M., Akhmadullina G.I. Bone Remodeling in Norm and in Primary Osteoporosis: The Significance of Bone Remodeling Markers. Russ. Arch. Intern. Med., 2018, vol. 8, no. 2, pp. 100–110. https://doi.org/10.20514/2226-6704-2018-8-2-100-110
34. Ignatenko G.A., Maylyan E.A., Nemsadze I.G., Rumyantseva Z.S., Churilov A.V., Glazkov I.S., Mirovich E.D. Rol’ tsitokinov v remodelirovanii kostnoy tkani v norme i patologii [Cytokines in Bone Tissue Remodeling in Norm and Pathology]. Tavricheskiy mediko-biologicheskiy vestnik, 2020, vol. 23, no. 1, pp. 133–139. https://doi.org/10.29039/2070-8092-2020-23-1-133-139
35. Ignatenko G.A., Nemsadze I.G., Mirovich E.D., Churilov A.V., Maylyan E.A., Glazkov I.S., Rumyantceva Z.S. The Role of Cytokines in Bone Remodeling and the Pathogenesis of Postmenopausal Osteoporosis. Med. Her. South Russ., 2020, vol. 11, no. 2, pp. 6–18 (in Russ.). https://doi.org/10.21886/2219-8075-2020-11-2-6-18
36. Xu J., Yu L., Liu F., Wan L., Deng Z. The Effect of Cytokines on Osteoblasts and Osteoclasts in Bone Remodeling in Osteoporosis: A Review. Front. Immunol., 2023, vol. 14. Art. no. 1222129. https://doi.org/10.3389/fimmu.2023.1222129
37. Galashina E.A., Gladkova E.V., Ul’yanov V.Yu. Biological Markers of Subchondral Bone Metabolism and Immune Inflammatory Factors in Early Stages of Primary Osteoarthritis (Review). J. Med. Biol. Res., 2022, vol. 10, no. 3, pp. 275–286. https://doi.org/10.37482/2687-1491-Z106
38. Zha L., He L., Liang Y., Qin H., Yu B., Chang L., Xue L. TNF-α Contributes to Postmenopausal Osteoporosis by Synergistically Promoting RANKL-Induced Osteoclast Formation. Biomed. Pharmacother., 2018, vol. 102, pp. 369–374. https://doi.org/10.1016/j.biopha.2018.03.080
39. Tsarenok S.Yu., Gorbunov V.V. Soderzhanie tsitokinov syvorotki krovi i sostoyanie mineral’noy plotnosti kostnoy tkani u zhenshchin s osteoporozom komorbidnym IBS [The Content of Cytokines of the Blood Serum and the State of Mineral Bone Density in Women with Osteoporosis Comorbid IHD]. Zabaykal’skiy meditsinskiy vestnik, 2015, no. 4, pp. 22–26.
40. Al-Daghri N.M., Aziz I., Yakout S., Aljohani N.J., Al-Saleh Y., Amer O.E., Sheshah E., Younis G.Z., Al-Badr F.B.M. Inflammation as a Contributing Factor Among Postmenopausal Saudi Women with Osteoporosis. Medicine (Baltimore), 2017, vol. 96, no. 4. Art. no. e5780. https://doi.org/10.1097/MD.0000000000005780
41. Maylyan E.A., Reznichenko N.A., Ignatenko G.A. Syvorotochnye urovni tsitokinov pri postmenopauzal’nom osteoporoze [Cytokines Serum Levels in Postmenopausal Osteoporosis]. Krymskiy zhurnal eksperimental’noy i klinicheskoy meditsiny, 2018, vol. 8, no. 1, pp. 36–42.
42. Sagalovsky S., Kunze P., Schönert M. Rol’ tsitokinovoy sistemy RANKL-RANK-OPG i katepsina K v patogeneze osteoporoza: dostizheniya i perspektivy v lechenii zabolevaniya [The Role of Cytokine System RANKL-RANK-OPG and Cathepsin K in the Pathogenesis of Osteoporosis: Achievements and Perspectives in the Treatment of Disease]. Klinitsist, 2012, no. 2, pp. 9–16. https://doi.org/10.17650/1818-8338-2012-6-2-9-16
43. Rozhnova O.M., Falameeva O.V., Sadovoy M.A. Patofiziologiya kostnoy tkani pri osteoporoze (obzor literatury) [Pathophysiology of Bone Tissue in Osteoporosis (Review)]. Mezhdunarodnyy zhurnal prikladnykh i fundamentalnykh issledovaniy, 2015, no. 9, pt. 4, pp. 666–669.
44. Ono T., Hayashi M., Sasaki F., Nakashima T. RANKL Biology: Bone Metabolism, the Immune System, and Beyond. Inflamm. Regen., 2020, vol. 40. Art. no. 2. https://doi.org/10.1186/s41232-019-0111-3
45. Azizieh F.Y., Shehab D., Jarallah K.A., Gupta R., Raghupathy R. Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women with Normal or Low Bone Mineral Density. Biomark. Insights, 2019, vol. 14. Art. no. 1177271919843825. https://doi.org/10.1177/1177271919843825
46. Astreyko M.O. Rol’ markerov regulyatsii osteoklastogeneza pri osteoporoze [Role of the Markers of Osteoclastogenesis Regulation in Osteoporosis]. Byulleten’ Severnogo gosudarstvennogo meditsinskogo universiteta, 2020, no. 1, pp. 225–226.
47. Ramli F.F., Chin K.-Y. A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures. Diagnostics (Basel), 2020, vol. 10, no. 3. Art. no. 145. https://doi.org/10.3390/diagnostics10030145